NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date and time:** Wednesday 15 December 2021

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Dr Lindsay Smith (Vice Chair) Items 1 to 5.2.2
3. Martin Bradley Present for all items
4. Dr Matthew Bradley Items 1 to 4.2.2
5. Professor Sofia Dias Present for all items
6. Chris Herring Present for all items
7. Dr Andrew Hitchings Items 5 to 6.2.2
8. Dr Robert Hodgson Items 1 to 4.2.2
9. Dr Bernard Khoo Present for all items
10. Ivan Koychev Items 1 to 5.2.2
11. Dr Guy Makin Present for all items
12. Professor David Meads Items 5 to 6.2.2
13. Giles Monnickendam Present for all items
14. Malcolm Oswald Present for all items
15. Dr Rebecca Payne Present for all items
16. Carole Pitkeathley Present for all items
17. Baljit Singh Present for all items
18. Professor John Watkins Items 1 to 4.2.2
19. Dr Ed Wilson Present for all items

NICE staff present

Linda Landells, Associate Director Items 1 to 4.2.2 & 6 to 6.2.2

Jasdeep Hayre, Associate Director Items 5 to 5.2.2

Louise Jafferally, Project Manager Items 1 to 4.2.2

Gavin Kenny, Project Manager Items 5 to 5.2.2

Hannah Nicholas, Health Technology Assessment Adviser Items 1 to 4.2.2

Caron Jones, Health Technology Assessment Adviser Items 5 to 5.2.2

Charlie Hewitt, Health Technology Assessment Adviser Items 6 to 6.2.2

Lizzie Bell, Health Technology Assessment Analyst, Items 1 to 4.2.2

Summaya Muhammed, Health Technology Assessment Analyst Items 5 to 5.2.2

Ziqi Zhou, Health Technology Assessment Analyst Items 5 to 5.2.2

Zain Hussain, Health Technology Assessment Analyst Items 6 to 6.2.2

Emily Eaton Turner, Technical Adviser, Commercial Risk Assessment, Present for all items

Ella Livingstone, Technical Adviser, Commercial Risk Assessment Items 1 to 4.2.2

Maroulla Whiteley, Business Analyst, RIA Items 1 to 5.1.3

Benjamin Pearce, Senior Medical Editor Items 1 to 4.2.2

Ruth Melville, Senior Medical Editor Items 5 to 6.2.2

Mandy Tonkinson, Patient Involvement Adviser, PIP Items 1 to 4.1.3

Catherine Pank, Assistant Project Manager Items 6 to 6.1.3

Lucinda Evans, Coordinator, MIP Items 1 to 4.1.3 & 6 to 6.1.3

Lyn Davies, Coordinator, MIP Items 5 to 5.1.3

Gemma Smith, Coordinator, COT Present for all items

Celia Mayers, Administrator, TA Items 1 to 4.2.2 & 6 to 6.2.2

Ismahan Abdullah, Administrator, TA Items 5 to 5.2.2

Laura Kelly, Administrator, COT Items 1 to 4.2.2

External review group representatives present

Peter Auguste, Warwick Evidence Items 1 to 4.1.3

Xavier Armoiry, Warwick Evidence Items 1 to 4.1.3

Robert Wolff, Kleijnen Systematic Reviews Ltd (KSR) Items 5 to 5.1.3

Thea Van Asselt, Kleijnen Systematic Reviews Ltd (KSR) Items 5 to 5.1.3

Paul Tappenden, School of Health and Related Research (ScHARR) Items 6 to 6.1.3

Clinical & patient experts present

Professor Peter Clark, CDF Clinical Lead, NHS England, Items 1 to 5.2.2

Professor. Gordon Cook, Clinical Director in Haematology, clinical expert nominated by Takeda, Items 1 to 4.1.3

Professor Graham Jackson, Consultant Haematologist, clinical expert nominated by Takeda, Items 1 to 4.1.3

Shelagh McKinlay, Patient expert nominated by Myeloma UK, Items 1 to 4.1.3

David Sinclair, Patient expert nominated by Myeloma UK, Items 1 to 4.1.3

Dr Alastair Greystoke, Consultant Medical Oncologist & Honorary Senior Lecturer, clinical expert nominated by Amgen, Items 5 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Dr Megan John welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meetings held on Thursday 14 October 2021 and Thursday 11 November 2021

### Appraisal of Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (CDF review of TA505) [ID1635]

* 1. Part 1 – Open session
     1. The chair welcomed the invited clinical and patient experts, National Clinical lead for Cancer drugs fund, external review group representatives, members of the public and company representatives from Takeda UK.
     2. The chair asked all committee members, clinical and patient experts, National Clinical lead for Cancer drugs fund, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Ed Wilson declared financial interests as Aspen, Celgene, Consilient Health, Janssen and Takeda are or have been clients of the company for which he works but they have not worked on any of the named compounds in the last 12 months. It was agreed his declaration would not prevent Dr Wilson from participating in discussions on this appraisal.
* Committee member Dr Matthew Bradley declared a non-financial professional interest as the company he is employed by holds a licence for a medicine used late in the treatment line which is not approved for use by NICE. It was agreed his declaration would not prevent Dr Bradley from participating in discussions on this appraisal.
* Committee member Professor David Meads declared non-financial professional interests as the University of Leeds has received funding from Takeda, Celgene and Janssen for research in a related area. He also currently works on a clinical trial that includes the therapies in the appraisal. As a direct conflict Professor Meads did not attend discussions on this appraisal.
* Nominated clinical expert Professor Gordon Cook declared financial interests as he has received consultancy fees and speaker bureau remuneration from Takeda, BMS Celgene, Roche and Jansson. He has also received consultancy fees from Sanofi, Roche and Cario Pharma and research funding from BMS. It was agreed his declaration would not prevent Professor Cook providing expert advice to committee.
* Nominated clinical expert Professor Graham Jackson declared financial interests as he has received honoraria for speaking, research funding and has been on advisory boards for both BMS and Takeda. It was agreed his declaration would not prevent Professor Jackson from providing expert advice to committee.
* Nominated patient expert Shelagh McKinlay declared financial interests as Myeloma UK has received grant funding from Takeda and other pharma companies. Staff members have received honoraria for boards and ads however this money all goes to the charity. It was agreed his declaration would not prevent Ms McKinlay providing expert advice to committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Professor John Watkins, Dr Robert Hodgson and Malcolm Oswald.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external review group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10781>

### Appraisal of sotorasib for previously treated KRAS G12C mutated, locally advanced or metastatic non-small-cell lung cancer [ID3780]

* 1. Part 1 – Open session
     1. The chair Dr Lindsay Smith welcomed the invited clinical expert, National Clinical lead for Cancer drugs fund, external review group representatives, members of the public and company representatives from Amgen UK.
     2. The chair asked all committee members, clinical expert, National Clinical lead for Cancer drugs fund, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared non-financial professional interests as the University of Leeds has received funding from Amgen, BMS and Takeda for research in an un-related area. It was agreed his declaration would not prevent Professor Meads from participating in discussions on this appraisal.
* Committee member Dr Ed Wilson declared financial interests as Amgen, Astra Zeneca, BMS, Consilient, MSD, Novartis, Pfizer, Roche and Takeda are or have been clients of the company for which he works but they have not worked on any of the named compounds in the last 12 months. It was agreed his declarations would not prevent Dr Wilson from participating in discussions on this appraisal.
* Committee Member Dr Matthew Bradley holds shares in the company AstraZeneca, the manufacturer of dapagliflozin. as a direct conflict Dr Bradley did not attend discussions on this appraisal.
* Nominated clinical expert Dr Alastair Greystoke declared financial interests as he has received consultancy and speaker fees from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, MSD, Novartis, Pfizer and Roche, he is the also clinical lead for cancer for the NEY Genomic Laboratory Hub responsible for genomic testing in his region and a member of the Genomics Test Evaluation Working Group. It was agreed his declaration would not prevent Dr Greystoke from providing expert advice to committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Ed Wilson, Dr Guy Makin and Malcolm Oswald.
  1. Part 2b – Closed session (company representatives, professional expert, external review group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10639>

### Appraisal of dapagliflozin for treating chronic kidney disease [ID3866]

* 1. Part 1 – Open session
     1. The chair Dr Megan John welcomed the external review group representatives, members of the public and company representatives from AstraZeneca
     2. The chair asked all committee members, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared non-financial professional interests as the University of Leeds has received funding from Takeda and Sanofi for research in an un-related area. It was agreed his declaration would not prevent Professor Meads from participating in discussions on this appraisal.
* Committee member Dr Ed Wilson declared financial interests as AstraZeneca Consilient Health, Lupin Healthcare, Novartis, Pfizer, Sanofi and Takeda are or have been clients of his company in the last 3 years, but they have not worked on this appraisal. It was agreed his declaration would not prevent Dr Wilson from participating in discussions on this appraisal.
* Committee Member Dr Matthew Bradley holds shares in the company AstraZeneca, the manufacturer of dapagliflozin. as a direct conflict Dr Bradley did not attend discussions on this appraisal.
* Committee member Dr Ivan Koychev declared non-financial professional interests as he is currently holding a National Institute of Health Research NIHR Development and Skills Enhancement Award as part of which he is working directly with the cardiovascular and neuroscience teams of AstraZeneca. He is also an investigator on trials funded by Novo Nordisk that examine the utility of diabetic agents for Alzheimer's disease. As a direct conflict Dr Koychev did not attend discussions on this appraisal.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, external review group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10808>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Wednesday 12 January 2022 and will start promptly at 09.30.